1. Altar, C.A., Carhart, J., Allen, J.D., Hall-Flavin, D., Winner, J., Dechairo, B., 2015. Clinical Utility of Combinatorial Phar macogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies. Mol. Neuropsychiatry 1, 145–155. https://doi.org/10.1159/000430915
2.
Appelbaum, P.S., Benston, S., 2017. Anticipating the Ethical Challenges of Psychiatric Genetic Testing. Curr. Psychiatry Rep. 19, 39. https://doi.org/10.1007/s11920-017-0790-x
3.
Austin, J., 2013. Genetic Testing for Psychiatric Disorders: Its Current Role in Clinical Psychiatric Practice 30.
4.
Bassett, A.S., Costain, G., Alan Fung, W.L., Russell, K.J., Pierce, L., Kapadia, R., Carter, R.F., Chow, E.W.C., Forsythe, P.J., 2010. Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. J. Psychiatr. Res. 44, 1005–1009. https://doi.org/10.1016/j.jpsychires.2010.06.013
5.
Bassett, A.S., Lowther, C., Merico, D., Costain, G., Chow, E.W.C., van Amelsvoort, T., McDonald-McGinn, D., Gur, R.E., Swillen, A., Van den Bree, M., Murphy, K., Gothelf, D., Bearden, C.E., Eliez, S., Kates, W., Philip, N., Sashi, V., Campbell, L., Vorst man, J., Cubells, J., Repetto, G.M., Simon, T., Boot, E., Heung, T., Evers, R., Vingerhoets, C., van Duin, E., Zackai, E., Vergaelen, E., Devriendt, K., Vermeesch, J.R., Owen, M., Murphy, C., Mi chaelovosky, E., Kushan, L., Schneider, M., Fremont, W., Busa, T., Hooper, S., McCabe, K., Duijff, S., Isaev, K., Pellecchia, G., Wei, J., Gazzellone, M.J., Scherer, S.W., Emanuel, B.S., Guo, T., Morrow, B.E., Marshall, C.R., International 22q11.2DS Brain and Behavior Consortium, 2017. Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome. Am. J. Psychiatry 174, 1054–1063. https://doi.org/10.1176/appi.ajp.2017.16121417.
6.
Cardno, A.G., Owen, M.J., 2014. Genetic Relationships Be tween Schizophrenia, Bipolar Disorder, and Schizoaffective Disorder. Schizophr. Bull. 40, 504–515. https://doi.org/10.1093/schbul/sbu016
7.
Costain, G., Esplen, M.J., Toner, B., Hodgkinson, K.A., Bas sett, A.S., 2014a. Evaluating Genetic Counseling for Family Members of Individuals With Schizophrenia in the Molecu lar Age. Schizophr. Bull. 40, 88–99. https://doi.org/10.1093/schbul/sbs124
8.
Costain, G., Esplen, M.J., Toner, B., Scherer, S.W., Meschi no, W.S., Hodgkinson, K.A., Bassett, A.S., 2014b. Evaluating Genetic Counseling for Individuals With Schizophrenia in the Molecular Age. Schizophr. Bull. 40, 78–87. https://doi.org/10.1093/schbul/sbs138
9.
Dean, L., 2012. Carbamazepine Therapy and HLA Genotype, in: Pratt, V.M., McLeod, H.L., Rubinstein, W.S., Scott, S.A., Dean, L.C., Kattman, B.L., Malheiro, A.J. (Eds.), Medical Ge netics Summaries. National Center for Biotechnology Infor mation (US), Bethesda (MD).
10.
Foley, C., Corvin, A., Nakagome, S., 2017. Genetics of Schizo phrenia: Ready to Translate? Curr. Psychiatry Rep. 19, 61. https://doi.org/10.1007/s11920-017-0807-5
11.
Friesen, P., Lawrence, R.E., Brucato, G., Girgis, R.R., Dixon, L., 2016. Hopes and Expectations Regarding Genetic Testing for Schizophrenia Among Young Adults at Clinical High-Risk for Psychosis: J. Psychiatr. Pract. 22, 442–449. https://doi.org/10.1097/PRA.0000000000000188
12.
Fung, W.L.A., McEvilly, R., Fong, J., Silversides, C., Chow, E., Bassett, A., 2010. Elevated Prevalence of Generalized Anxiety Disorder in Adults With 22q11.2 Deletion Syndrome. Am. J. Psychiatry 167, 998–998. https://doi.org/10.1176/appi.ajp.2010.09101463
13.
Fusar-Poli, P., Cappucciati, M., Borgwardt, S., Woods, S.W., Addington, J., Nelson, B., Nieman, D.H., Stahl, D.R., Rutigli ano, G., Riecher-Rössler, A., Simon, A.E., Mizuno, M., Lee, T.Y., Kwon, J.S., Lam, M.M.L., Perez, J., Keri, S., Amminger, P., Metzler, S., Kawohl, W., Rössler, W., Lee, J., Labad, J., Zier mans, T., An, S.K., Liu, C.-C., Woodberry, K.A., Braham, A., Corcoran, C., McGorry, P., Yung, A.R., McGuire, P.K., 2016. Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk: A Meta-analytical Stratification. JAMA Psychiatry 73, 113. https://doi.org/10.1001/jamapsychia try.2015.2324
14.
Hauser, J., 2011. Konsultacja genetyczna w psychiatrii – kon trowersje. Psychiatr. Po Dyplomie 8.
15.
Hicks, J., Bishop, J., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., Skaar, T., Scott, S., Stingl, J., Klein, T., Caudle, K., Gaedigk, A., 2015. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin. Pharmacol. Ther. 98, 127–134. https://doi.org/10.1002/cpt.147
16.
Hill, M.K., Sahhar, M., 2006. Genetic counselling for psy chiatric disorders. Med. J. Aust. 185, 507–510.
17.
Hirschtritt, M.E., Besterman, A.D., Ross, D.A., 2016. Psychiat ric Pharmacogenomics: How Close Are We? Biol. Psychiatry 80, e63–e65. https://doi.org/10.1016/j.biopsych.2016.08.007
18.
https://research.bournemouth.ac.uk/wp-content/uploads/2016/10/PG4GC3.pdf, 2020.
19.
https://www.cost.eu/cost-action/enhancing-psychiatric genetic-counselling-testing-and-training-in-europe/#tab s|Name:overview, 2020.
20.
Inglis, A., Koehn, D., McGillivray, B., Stewart, S.E., Austin, J., 2015. Evaluating a unique, specialist psychiatric genetic counseling clinic: uptake and impact: Evaluating a special ist psychiatric genetic counseling clinic. Clin. Genet. 87, 218–224. https://doi.org/10.1111/cge.12415
21.
Lyus, V.L., 2007. The importance of genetic counseling for individuals with schizophrenia and their relatives: Potential clients’ opinions and experiences. Am. J. Med. Genet. B Neu ropsychiatr. Genet. 144B, 1014–1021. https://doi.org/10.1002/ajmg.b.30536
22.
Moldovan, R., McGhee, K.A., Coviello, D., Hamang, A., Inglis, A., Ingvoldstad Malmgren, C., Johansson‐Soller, M., Lau rino, M., Meiser, B., Murphy, L., Paneque, M., Papsuev, O., Pawlak, J., Rovira Moreno, E., Serra‐Juhe, C., Shkedi‐Rafid, S., Laing, N., Voelckel, M., Watson, M., Austin, J.C., 2019. Psychiatric genetic counseling: A mapping exercise. Am. J. Med. Genet. B Neuropsychiatr. Genet. 180, 523–532. https://doi.org/10.1002/ajmg.b.32735.
23.
Monaco, L.C., Conway, L., Valverde, K., Austin, J.C., 2010. Exploring Genetic Counselors’ Perceptions of and Attitudes towards Schizophrenia. Public Health Genomics 13, 21–26. https://doi.org/10.1159/000210096.
24.
Nassan, M., Nicholson, W.T., Elliott, M.A., Rohrer Vitek, C.R., Black, J.L., Frye, M.A., 2016. Pharmacokinetic Pharmacog enetic Prescribing Guidelines for Antidepressants: A Tem plate for Psychiatric Precision Medicine. Mayo Clin. Proc. 91, 897–907. https://doi.org/10.1016/j.mayocp.2016.02.023
25.
Nelson, B., Amminger, G.P., Thompson, A., Wood, S.J., Yung, A.R., McGorry, P.D., 2020. Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evi dence). Front. Psychiatry 11, 488. https://doi.org/10.3389/fpsyt.2020.00488
26.
Nurnberger, J.I., Austin, J., Berrettini, W.H., Besterman, A.D., DeLisi, L.E., Grice, D.E., Kennedy, J.L., Moreno-De-Luca, D., Potash, J.B., Ross, D.A., Schulze, T.G., Zai, G., 2018. What Should a Psychiatrist Know About Genetics?: Review and Recommendations From the Residency Education Committee of the International Society of Psychiatric Genetics. J. Clin. Psychiatry 80. https://doi.org/10.4088/JCP.17nr12046
27.
Peay, H., Austin, J., 2011. How to talk with families about genet ics and psychiatric illness. W.W. Norton, New York; London.
28.
Propping, P., 2005. The biography of psychiatric genetics: From early achievements to historical burden, from an anxious soci ety to critical geneticists. Am. J. Med. Genet. B Neuropsychiatr. Genet. 136B, 2–7. https://doi.org/10.1002/ajmg.b.30188.
29.
Resta, R., Biesecker, B.B., Bennett, R.L., Blum, S., Estabrooks Hahn, S., Strecker, M.N., Williams, J.L., 2006. A New Defi nition of Genetic Counseling: National Society of Genetic Counselors’ Task Force Report. J. Genet. Couns. 15, 77–83. https://doi.org/10.1007/s10897-005-9014-3
30.
Revised recommendations for Celexa (citalopram hydrobro mide) related to a potential risk of abnormal heart rhythms with high doses [FDA Drug Safety Communication]. US Food and Drug Administration website. https://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. Published March 28, 2012., n.d.
31.
Rybakowski, J.K., 2014. Response to Lithium in Bipolar Dis order: Clinical and Genetic Findings. ACS Chem. Neurosci. 5, 413–421. https://doi.org/10.1021/cn5000277
32.
Rybakowski J.K., 2019. Lit. Niezwykły lek w psychiatrii., 1st ed. Termedia, Poznań.
33.
Schmidt, S.J., Schultze-Lutter, F., Schimmelmann, B.G., Ma ric, N.P., Salokangas, R.K.R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., Mor rison, A., Raballo, A., Klosterkötter, J., Ruhrmann, S., 2015. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur. Psychiatry 30, 388–404. https://doi.org/10.1016/j.eurpsy.2015.01.013
34.
Serretti, A., 2017. Genetics and pharmacogenetics of mood disorders. Psychiatr. Pol. 51, 197–203. https://doi.org/10.12740/PP/68914
35.
Tsuang, D.W., Faraone, S.V., Tsuang, M.T., 2001. Genetic counseling for psychiatric disorders. Curr. Psychiatry Rep. 3, 138–143. https://doi.org/10.1007/s11920-001-0011-4
36.
US Food and Drug Administration website, www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/, n.d.
37.
van Westrhenen, R., Aitchison, K.J., Ingelman-Sundberg, M., Jukić, M.M., 2020. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Front. Psychiatry 11, 94. https://doi.org/10.3389/fpsyt.2020.00094
38.
Yoshida, K., Müller, D.J., 2019. Pharmacogenetics of An tipsychotic Drug Treatment: Update and Clinical Impli cations. Mol. Neuropsychiatry 5, 1–26. https://doi.org/10.1159/000492332
